
Please try another search
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
David T. Hung | 66 | 2018 | Founder, President, CEO & Chairman |
Kathryn E. Falberg | 64 | 2020 | Independent Director |
Kim D. Blickenstaff | 73 | 2019 | Independent Director |
Robert B. Bazemore | 57 | 2020 | Lead Independent Director |
William Anthony Vernon | 69 | 2019 | Independent Director |
Wassim Abida | - | 2023 | Member of Scientific Advisory Board |
Joyce Ann O'Shaughnessy | - | 2023 | Member of Scientific Advisory Board |
Allyson J. Ocean | 53 | 2023 | Member of Scientific Advisory Board |
Johann de Bono | - | 2023 | Member of Scientific Advisory Board |
Gordon B. Mills | - | 2023 | Member of Scientific Advisory Board |
Xiangmin Cui | 57 | 2024 | Independent Director |
Robert D. Mashal | 65 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review